

AMENDMENTS TO THE CLAIMS

1. (Currently amended): A method of ~~preventing~~ treating Type I diabetes, comprising:
~~identifying a subject suseceptible to or suffering from Type I diabetes; and~~
administering ~~to the subject~~ a pharmaceutically effective amount of a p38 mitogen activated protein (MAP) kinase inhibitor sufficient to prevent onset of Type I diabetes, in a subject in need thereof.
2. (Original): The method of claim 1, wherein the subject presents an increased immune response against a heat shock protein.
3. (Original): The method of claim 2, wherein the heat shock protein is HSP 60.
4. (Original): The method of claim 1, wherein said p38 MAP kinase inhibitor is selective for p38 α , p38 β , p38 γ , or p38 δ .
5. (Currently amended): The method of claim 1, wherein said ~~patient~~ subject is a human.
6. (Currently amended): The method of claim 1, wherein administration of the p38 MAP kinase inhibitor results in a decrease in blood glucose levels. A method of decreasing blood glucose levels, comprising:
~~providing to a subject with elevated blood glucose levels with a pharmaceutically effective amount of a p38 mitogen activated protein (MAP) kinase inhibitor sufficient to decrease blood glucose level in said patient.~~
- 7-8. (Canceled)
9. (Currently amended): The method of claim 1, wherein administration of the p38 MAP kinase inhibitor results in an inhibition in body weight loss in the subject. A method of inhibiting body weight loss in a subject suffering from Type I diabetes, comprising:
~~identifying the subject suffering from to Type I diabetes; and~~
~~providing the subject with a pharmaceutically effective amount of a p38 mitogen activated protein (MAP) kinase inhibitor sufficient to inhibit body weight loss in the subject.~~
- 10-11. (Canceled)